Skeletal morbidity in lung cancer patients with bone metastases: Demonstrating the need for early diagnosis and treatment with bisphosphonates

Lung Cancer

Volumn 67, Issue 1, 2010, Pages 4-11

  Langer, Corey ^a   Hirsh, Vera ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

Bisphosphonates; Bone metastases; Non small cell lung cancer; Zoledronic acid

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; BISPHOSPHONIC ACID DERIVATIVE; CARBOPLATIN; CISPLATIN; CLODRONIC ACID; DOCETAXEL; ETIDRONIC ACID; FLUORODEOXYGLUCOSE F 18; IBANDRONIC ACID; PACLITAXEL; PAMIDRONIC ACID; PLACEBO; RISEDRONIC ACID; ZOLEDRONIC ACID;

ADJUVANT THERAPY; ANEMIA; ANTINEOPLASTIC ACTIVITY; BONE BIOPSY; BONE DISEASE; BONE METASTASIS; BONE PAIN; BONE RADIOGRAPHY; BONE SCINTISCANNING; CANCER CELL CULTURE; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; COST CONTROL; CREATININE BLOOD LEVEL; DENTAL CARE; DISEASE FREE SURVIVAL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EARLY DIAGNOSIS; EARLY INTERVENTION; HEALTH CARE COST; HUMAN; HYPERCALCEMIA; INCIDENCE; INHIBITION KINETICS; JAW OSTEONECROSIS; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; MEDICAL LITERATURE; MEDLINE; MORBIDITY; MULTIPLE CYCLE TREATMENT; NAUSEA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOLYSIS; OSTEOSARCOMA; OVERALL SURVIVAL; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK REDUCTION; SENSITIVITY AND SPECIFICITY; SIDE EFFECT;

BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; DIPHOSPHONATES; HUMANS; IMIDAZOLES; INCIDENCE; LUNG NEOPLASMS; NEOPLASM METASTASIS;

EID: 71849091513     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2009.08.020     Document Type: Review

References (78)

1. Giaccone G., Gallegos Ruiz M., Le Chevalier T., et al. Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study. Clin Cancer Res 12 (2006) 6049-6055
2. Sandler A., Gray R., Perry M.C., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355 (2006) 2542-2550
3. Coleman R.E. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 27 (2001) 165-176
4. Iordanidou L., Trivizaki E., Saranti S., et al. Is there a role of whole body bone scan in early stages of non small cell lung cancer patients. J BUON 11 (2006) 491-497
5. Shaham D., Breuer R., Copel L., et al. Computed tomography screening for lung cancer: applicability of an international protocol in a single-institution environment. Clin Lung Cancer 7 (2006) 262-267
6. Rosen L.S., Gordon D., Tchekmedyian S., et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial-the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 21 (2003) 3150-3157
7. Fukuoka M., Yano S., Giaccone G., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (the IDEAL 1 trial). J Clin Oncol 21 (2003) 2237-2246 [corrected]
8. Berenson J.R., Rajdev L., and Broder M. Managing bone complications of solid tumors. Cancer Biol Ther 5 (2006) 1086-1089
9. Coleman R.E. Management of bone metastases. Oncologist 5 (2000) 463-470
10. Coleman R.E. Bisphosphonates: clinical experience. Oncologist 9 suppl. 4 (2004) 14-27
11. Kakonen S.M., and Mundy G.R. Mechanisms of osteolytic bone metastases in breast carcinoma. Cancer 97 suppl. (2003) 834-839
12. Guise T.A., Mohammad K.S., Clines G., et al. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res 12 suppl. (2006) 6213s-6216
13. Goltzman D., Karaplis A.C., Kremer R., and Rabbani S.A. Molecular basis of the spectrum of skeletal complications of neoplasia. Cancer 88 suppl. (2000) 2903-2908
14. Koizumi M., Yamada Y., Takiguchi T., et al. Bone metabolic markers in bone metastases. J Cancer Res Clin Oncol 121 (1995) 542-548
15. Rosen L.S., Gordon D., Tchekmedyian N.S., et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer 100 (2004) 2613-2621
16. Lipton A. Pathophysiology of bone metastases: how this knowledge may lead to therapeutic intervention. J Support Oncol 2 (2004) 205-213 [discussion follows]
17. Rosen L.S., Gordon D., Kaminski M., et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 98 (2003) 1735-1744
18. Saad F., Gleason D.M., Murray R., et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96 (2004) 879-882
19. Hirsh V., Tchekmedyian N.S., Rosen L.S., Zheng M., and Hei Y.J. Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors: analysis based on history of skeletal complications. Clin Lung Cancer 6 (2004) 170-174
20. Hillner B.E., Ingle J.N., Chlebowski R.T., et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21 (2003) 4042-4057
21. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: prostate cancer. http://www.nccn.org/professionals/physician_gls/PDF/prostate.pdf. Accessed September 17, 2008.
22. Mundy G.R. Mechanisms of bone metastasis. Cancer 80 suppl. (1997) 1546-1556
23. Saad F., and Schulman C.C. Role of bisphosphonates in prostate cancer. Eur Urol 45 (2004) 26-34
24. Sabino M.A., and Mantyh P.W. Pathophysiology of bone cancer pain. J Support Oncol 3 (2005) 15-24
25. Pfister D.G., Johnson D.H., Azzoli C.G., et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 22 (2004) 330-353
26. Baum R.P., Hellwig D., and Mezzetti M. Position of nuclear medicine modalities in the diagnostic workup of cancer patients: lung cancer. Q J Nucl Med Mol Imaging 48 (2004) 119-142
27. Silvestri G.A., Tanoue L.T., Margolis M.L., Barker J., and Detterbeck F. The noninvasive staging of non-small cell lung cancer: the guidelines. Chest 123 suppl. (2003) 147S-156S
28. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: non-small cell lung cancer. http://www.nccn.org/professionals/physician_gls/PDF/nscl.pdf. Accessed September 17, 2008.
29. Bury T., Barreto A., Daenen F., et al. Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancer. Eur J Nucl Med 25 (1998) 1244-1247
30. Gayed I., Vu T., Johnson M., Macapinlac H., and Podoloff D. Comparison of bone and 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography in the evaluation of bony metastases in lung cancer. Mol Imaging Biol 5 (2003) 26-31
31. Hetzel M., Arslandemir C., Konig H.H., et al. F-18 NaF PET for detection of bone metastases in lung cancer: accuracy, cost-effectiveness, and impact on patient management. J Bone Miner Res 18 (2003) 2206-2214
32. Lipton A., Theriault R.L., Hortobagyi G.N., et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 88 (2000) 1082-1090
33. Berenson J.R., Lichtenstein A., Porter L., et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol 16 (1998) 593-602
34. Saad F. Clinical benefit of zoledronic acid for the prevention of skeletal complications in advanced prostate cancer. Clin Prostate Cancer 4 (2005) 31-37
35. Lipton A. Bisphosphonate therapy in the oncology setting. Expert Opin Emerg Drugs 8 2 (2003) 469-488
36. Delea T., McKiernan J., Liss M., et al. Cost of skeletal complications in patients with bone metastases of lung cancer [abstract]. Lung Cancer 41 suppl. 2 (2003) S7 [Abstract O9]
37. Delea T., Langer C., McKiernan J., et al. The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer. Oncology 67 (2004) 390-396
38. Saba N., and Khuri F. The role of bisphosphonates in the management of advanced cancer with a focus on non-small-cell lung cancer. Part 2: Clinical studies and economic analyses. Oncology 68 (2005) 18-22
39. Ripamonti C., and Fulfaro F. Malignant bone pain: pathophysiology and treatments. Curr Rev Pain 4 (2000) 187-196
40. Saad F., Lipton A., Cook R., et al. Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer 110 (2007) 1860-1867
41. Weinfurt K.P., Li Y., Castel L.D., et al. The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann Oncol 16 (2005) 579-584
42. Delea T.E., McKiernan J., Brandman J., et al. Impact of skeletal complications on total medical care costs among patients with bone metastases of lung cancer. J Thorac Oncol 1 (2006) 571-576
43. Green J.R. Preclinical profile and anticancer potential of zoledronic acid. In: Birch E.V. (Ed). Trends in bone cancer research 24 (2006), Nova Science Publishers, Inc, New York 217-245
44. Fleisch H. Development of bisphosphonates. Breast Cancer Res 4 (2002) 30-34
45. Green J.R. Bisphosphonates: preclinical review. Oncologist 9 suppl. 4 (2004) 3-13
46. Green J. Zoledronate: the preclinical pharmacology. Br J Clin Pract Suppl 87 (1996) 16-18 [discussion follows]
47. Green J.R., Muller K., and Jaeggi K.A. Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res 9 (1994) 745-751
48. Bukowski R., Rosen L., Gordon D., et al. Long-term therapy with zoledronic acid is effective and safe in reducing the risk of skeletal complications in patients with bone metastases from non-small cell lung cancer (NSCLC) [poster]. 10th World Conference on Lung Cancer. August 10-14, Vancouver, British Columbia, Canada (2003) [Abstract 150]
49. Conte P., and Guarneri V. Safety of intravenous and oral bisphosphonates and compliance with dosing regimens. Oncologist 9 suppl. 4 (2004) 28-37
50. Weitzman R., Sauter N., Eriksen E.F., et al. Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients-May 2006. Crit Rev Oncol Hematol 62 (2007) 148-152
51. Zometa [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2005.
52. Durie B.G., Katz M., and Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 353 (2005) 99-102 [discussion follows]
53. Hoff A.O., Toth B.B., Altundag K., et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 23 (2008) 826-836
54. Pozzi S., Marcheselli R., Sacchi S., et al. Bisphosphonate-associated osteonecrosis of the jaw: a review of 35 cases and an evaluation of its frequency in multiple myeloma patients. Leuk Lymphoma 48 (2007) 56-64
55. Dimopoulos M.A., Kastritis E., Bamia C., et al. Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol 20 (2009) 117-120
56. Montefusco V., Gay F., Spina F., et al. Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates. Leuk Lymphoma 49 (2008) 2156-2162
57. Ripamonti C.I., Maniezzo M., Campa T., et al. Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann Oncol 20 (2009) 137-145
58. Ripamonti C., Maniezzo M., Ghiringhelli R., et al. Medical ozone oil suspension applications heal osteonecrosis of the jaw (ONJ) in patients treated with bisphosphonates (BPs): preliminary results of a single institution protocol [poster]. Primary Therapy of Early Breast Cancer 11th International Conference. March 11-14, St. Gallen, Switzerland (2009) [Poster 194]
59. Brown J.E., Cook R.J., Major P., et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 97 (2005) 59-69
60. Pectasides D., Nikolaou M., Farmakis D., et al. Clinical value of bone remodelling markers in patients with bone metastases treated with zoledronic acid. Anticancer Res 25 (2005) 1457-1463
61. Coleman R.E., Major P., Lipton A., et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 23 (2005) 4925-4935
62. Lipton A., Cook R., Saad F., et al. Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer 113 (2008) 193-201
63. Hirsh V., Major P.P., Lipton A., et al. Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity. J Thorac Oncol 3 (2008) 228-236
64. Green J.R. Antitumor effects of bisphosphonates. Cancer 97 suppl. (2003) 840-847
65. Matsumoto S., Kimura S., Segawa H., et al. Efficacy of combining the third generation bisphosphonate, zoledronate with imatinib mesylate in suppressing small cell lung cancer cell line proliferation [abstract]. Proc Am Soc Clin Oncol 22 suppl. (2003) 684 [Abstract 2750]
66. Berger W., Kubista B., Elbling L., Sutterluty H., and Micksche M. The N-containing bisphosphonate zoledronic acid exerts potent anticancer activity against non-small cell lung cancer cells by inhibition of protein geranylgeranylation [abstract]. Proc Am Assoc Cancer Res 46 (2005) [Abstract 4981]
67. Ozturk O.H., Bozcuk H., Burgucu D., et al. Cisplatin cytotoxicity is enhanced with zoledronic acid in A549 lung cancer cell line: preliminary results of an in vitro study. Cell Biol Int 31 (2007) 1069-1071
68. Gjyrezi A., O'Brate A., Chanel-Vos C., and Giannakakou P. Zoledronic acid synergizes with Taxol in an HDAC6-dependent manner: novel mechanistic implications for combination anticancer therapy with taxanes [abstract]. Proc Am Assoc Cancer Res (2007) [Abstract 1425]
69. Li Y.Y., Chang J.W., Chou W.C., et al. Zoledronic acid is unable to induce apoptosis, but slows tumor growth and prolongs survival for non-small-cell lung cancers. Lung Cancer 59 (2008) 180-191
70. Ory B., Heymann M.F., Kamijo A., et al. Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice. Cancer 104 (2005) 2522-2529
71. Matsumoto S., Kimura S., Segawa H., et al. Efficacy of the third-generation bisphosphonate, zoledronic acid alone and combined with anti-cancer agents against small cell lung cancer cell lines. Lung Cancer 47 (2005) 31-39
72. Landmeier S., Altvater B., Pscherer S., et al. Presentation of Epstein Barr virus (EBV) epitopes by activated human γδ T cells induces peptide-specific cytolytic CD8+ T cell expansion [abstract]. Blood 108 (2006) [Abstract 1738]
73. Fournier P.G., Chirgwin J.M., and Guise T.A. New insights into the role of T cells in the vicious cycle of bone metastases. Curr Opin Rheumatol 18 (2006) 396-404
74. Pandya K.J., Gajra A., Warsi G.M., et al. Multicenter, randomized, phase 2 study of zoledronic acid in combination with docetaxel and carboplatin in patients with unresectable stage IIIB or stage IV non-small cell lung cancer. Lung Cancer (2009 Jun 1) [Epub ahead of print]
75. Gnant M., Mlineritsch B., Schippinger W., et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 360 (2009) 679-691
76. Gnant M., Mlineritsch B., Luschin-Ebengreuth G., et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol 9 (2008) 840-849
77. US National Institutes of Health. A study to evaluate the safety and efficacy of zoledronic acid in the prevention or delaying of bone metastasis in patients with stage IIIA and IIIB non-small cell lung cancer. Available at: http://www.clinicaltrials.gov/ct2/show/NCT00172042?term=zoledronic+acid+ AND+lung+cancer&rank=1. Accessed September 17, 2008.
78. US National Institutes of Health. Non-small cell lung cancer study US75 (Z-PACT). Available at: http://www.clinicaltrials.gov/ct2/show/NCT00086268?term=zoledronic+acid+ AND+lung+cancer&rank=9. Accessed September 17, 2008.